Key point here: Actively looking at adding a second 'safety only...

Key point here: Actively looking at adding a second 'safety only ' study in non-breast cancer affected patients.

I like this. Clearly the company is looking to shave time off the commercialisation timeline by incorporating participants with breast cancer into Phase 1 trial in order to partially determine efficacy, but if safety is the ultimate goal of a P1 study, any body will indeed do.

I reiterate: the company's value prop has not changed, the validity of the offering has not changed, the size of the addressable market has not changed. The only thing that's changed is the color of the undies of a portion of the holders due to a minor delay.

I won't be out of this stock when the inevitable good news drops.